Solid GT Obtains $42,500,000 Series B Financing

  • Feed Type
  • Date
    11/5/2015
  • Company Name
    Solid GT
  • Mailing Address
    One Broadway Cambridge, MA 02142 USA
  • Company Description
    Solid exists to bridge the gap and advance treatments to patients. Well-capitalized and focused on results, we are purpose-built to identify and develop the most promising approaches to treat and cure DMD.
  • Website
    http://www.solidbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $42,500,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    which the company will use to advance the development of its novel gene therapy platform for Duchenne muscular dystrophy (DMD), a fatal and untreatable condition.
  • M&A Terms
  • Venture Investor
    Perceptive Advisors
  • Venture Investor
    Biogen Idec
  • Venture Investor
    Janus Capital
  • Venture Investor
    Undisclosed

Trending on Xconomy